Table 3.

Frequency of most common adverse events (> 10% of total cases) by first-line therapy group

	Total	1L therapy		P value
	N = 654 (%)	nab-P + G (%)	FFX (%)
Anemia	45.43	45.50	45.34	0.98
Febrile neutropenia	12.49	9.21	16.23	0.07
Neutropenia	32.73	33.38	31.99	0.79
Thrombocytopenia	24.97	27.11	22.52	0.34
Diarrhea	29.46	20.51	39.71	< 0.001*
Stomatitis	10.10	3.62	17.52	< 0.001*
Abdominal pain	19.48	21.18	17.54	0.38
Alopecia	16.45	16.34	16.57	0.96
Decreased appetite	27.79	25.81	30.06	0.39
Dehydration	18.54	14.93	22.67	0.08
Fatigue	37.28	31.80	43.56	< 0.05*
Mucositis	11.37	5.16	18.48	< 0.001*
Nausea and vomiting	23.25	18.27	28.94	< 0.05*

FFX FOLFIRINOX, nab-P + G nanoparticle albumin-bound paclitaxel/gemcitabine, 1L first-line

*P < 0.05